Binder Hagit 4
4 · NeuroSense Therapeutics Ltd. · Filed Mar 30, 2026
Research Summary
AI-generated summary of this filing
NeuroSense (NRSN) GM Hagit Binder Receives 200,000 Restricted Shares
What Happened
Hagit Binder, General Manager of NeuroSense Therapeutics Ltd. (NRSN), received an award/ grant of 200,000 restricted ordinary shares on March 26, 2026. The shares were issued at a $0.00 price (award), so the reported acquisition value is $0. This is a compensation grant rather than an open-market purchase or sale.
Key Details
- Transaction type/code: Award/Grant (A) — 200,000 restricted shares
- Transaction date: March 26, 2026; Form 4 filed March 30, 2026 (timely filing)
- Price: $0.00 per share; reported acquisition value $0
- Vesting: shares vest in equal quarterly installments over two years starting March 26, 2026, subject to continued service (see footnote)
- Trustee: shares are to be registered in the name of a trustee to qualify for Israeli Section 102 tax benefits (footnote)
- Shares owned after transaction: not specified in the provided filing details
Context
This is a standard restricted-share compensation grant to an executive; it is neither a market purchase (which some investors view as a bullish signal) nor a sale. The grant is subject to a two-year quarterly vesting schedule and trustee registration for Israeli tax treatment, meaning the recipient must remain employed to realize the full award.
Insider Transaction Report
- Award
Ordinary Shares
[F1][F2]2026-03-26+200,000→ 521,806 total
Footnotes (2)
- [F1]To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's 2018 Share Incentive Plan must be registered in the name of a trustee.
- [F2]The restricted shares vest in equal quarterly installments over a two-year period, commencing on the grant date of March 26, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date.